Biotech News
Related news
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
OCSOculis2026-05-11 20:07 EST
Oculis Reports Q1 2026 Financial Results and Provides Company Update
RHHBYRoche Holdings AG2026-09-23 05:00 EST
Change in Roche’s Board of Directors
MGTXMeiraGTx2026-09-23 12:00 EST
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-10-01 06:00 EST
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
OCSOculis2026-09-30 21:32 EST
Oculis Announces Resignation of Lionel Carnot from Board of Directors
OCSOculis2026-09-17 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-08-24 08:00 EST
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
OCSOculis2026-08-14 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Stock data
- Close
- 8.73 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States